Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Aliment Pharmacol Ther ; 36(11-12): 1067-75, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23072686

ABSTRACT

BACKGROUND: Patients with chronic atrophic gastritis have long-term gastric hypoacidity, and secondary hypergastrinaemia. Some also develop gastric ECL cells carcinoids (type 1 GC). Most type 1 GC remain indolent, but some metastasise. Patients undergo surveillance, and some are treated with somatostatin analogues, endoscopic resection or surgery. Netazepide (YF476) is a highly selective, potent and orally active gastrin receptor antagonist, which has anti-tumour activity in various rodent models of gastric neoplasia driven by hypergastrinaemia. Netazepide has been studied in healthy volunteers. AIM: To assess the effect of netazepide on type 1 GC. METHODS: Eight patients with multiple type 1 GC received oral netazepide once daily for 12 weeks, with follow-up at 12 weeks in an open-label, pilot trial. Upper endoscopy was performed at 0, 6, 12 and 24 weeks, and carcinoids were counted and measured. Fasting serum gastrin and chromogranin A (CgA) and safety and tolerability were assessed at 0, 3, 6, 9, 12 and 24 weeks. RESULTS: Netazepide was well tolerated. All patients had a reduction in the number and size of their largest carcinoid. CgA was reduced to normal levels at 3 weeks and remained so until 12 weeks, but had returned to pre-treatment levels at 24 weeks. Gastrin remained unchanged throughout treatment. CONCLUSIONS: The gastrin receptor antagonist netazepide is a promising new medical treatment for type 1 gastric carcinoids, which appear to be gastrin-dependent. Controlled studies and long-term treatment are justified to find out whether netazepide treatment can eradicate type 1 gastric carcinoids.


Subject(s)
Benzodiazepinones/therapeutic use , Carcinoid Tumor/drug therapy , Chromogranin A/blood , Phenylurea Compounds/therapeutic use , Receptor, Cholecystokinin B/antagonists & inhibitors , Stomach Neoplasms/drug therapy , Aged , Carcinoid Tumor/blood , Female , Gastrins/blood , Humans , Male , Middle Aged , Stomach Neoplasms/blood , Treatment Outcome
2.
Aliment Pharmacol Ther ; 36(7): 644-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22861200

ABSTRACT

BACKGROUND: Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and give hypergastrinemia secondary to gastric hypoacidity. PPI treatment therefore induces enterochromaffin-like (ECL) cell hyperplasia. Long-term hypergastrinemia in rodents and man also leads to ECL cell neoplasia. Whether long-term PPI treatment will induce ECL cell neoplasia in man has been disputed. AIM: To describe gastric carcinoids in two patients with a history of long-term PPI use. RESULTS: Two patients had been taking PPI for 12-13 years due to gastro-oesophageal reflux disease. At routine upper gastrointestinal endoscopy a solitary tumour was found in the oxyntic mucosa of both patients. Histology from the tumours showed in both cases a well-differentiated neuroendocrine tumour. Biopsies from flat oxyntic mucosa showed no signs of atrophic gastritis and a normal presence of parietal cells in both cases, but hyperplasia of ECL cells. The tumour in patient 1 was resected endoscopically. After cessation of PPI treatment the tumour regressed in patient 2 and the ECL cell hyperplasia regressed in both patients. In patient 2 serum gastrin and chromogranin A were elevated during PPI treatment, and normalised after cessation of treatment. In patient 1, unfortunately, we had serum only after treatment, and at that time both parameters were normal. CONCLUSION: These cases show that hypergastrinemia secondary to proton pump inhibitors treatment, like other causes of hypergastrinemia, may induce enterochromaffin-like cell carcinoids in man.


Subject(s)
Carcinoid Tumor/chemically induced , Enterochromaffin-like Cells/drug effects , Gastroesophageal Reflux/drug therapy , Proton Pump Inhibitors/adverse effects , Stomach Neoplasms/chemically induced , Aged , Biopsy , Carcinoid Tumor/pathology , Female , Gastric Mucosa/drug effects , Humans , Male , Middle Aged , Stomach Neoplasms/pathology , Time Factors
3.
J Comp Pathol ; 139(4): 194-201, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18817920

ABSTRACT

In humans and rodents the association between atrophic gastritis, hypergastrinemia and gastric neoplasia is well-documented. Gastric tumours are rare in dogs, but the Norwegian Lundehund (puffin dog) appears predisposed to the development of gastric neoplasia associated with chronic atrophic gastritis. The present study describes 8 Lundehunds with gastric neoplasia. Seven of these animals had concurrent chronic atrophic gastritis characterized by reduction in parietal cells and hyperplasia of neuroendocrine cells. Four of the tumours displayed neuroendocrine (enterochromaffin-like cell; ECL) differentiation, suggesting that hypergastrinemia secondary to fundic atrophy may be important in carcinogenesis. The Norwegian Lundehund may therefore represent a further animal model for the study of the role of gastrin in the induction of gastric neoplasia.


Subject(s)
Carcinoma, Neuroendocrine/veterinary , Dog Diseases/pathology , Gastritis/veterinary , Stomach Neoplasms/veterinary , Animals , Carcinoma, Neuroendocrine/complications , Carcinoma, Neuroendocrine/pathology , Dogs , Female , Gastritis/complications , Gastritis/pathology , Immunohistochemistry , Male , Stomach Neoplasms/complications , Stomach Neoplasms/pathology
4.
J Exp Clin Cancer Res ; 25(2): 213-21, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16918133

ABSTRACT

Pancreatic ductal adenocarcinomas can display disseminated neuroendocrine (NE) cells. Controversies exist as to their relative incidence, histogenesis, hormone production, and the prognostic implications of their presence. These issues were elucidated by means of a broad immunohistochemical (IHC) investigation of the resected specimens from 47 patients. Chromogranin A (CgA) was chosen as the major NE marker. In addition, the sensitivity of the conventional IHC procedure was increased by means of the TSA (Tyramide Signal Amplification) technique. In tumours with CgA immunoreactive (IR) cells, detected by the conventional or the TSA methods, these NE cells were further IHC analyzed, using antisera raised against a broad spectrum of neurohormonal peptides, serotonin, and IGF-1. The IHC observations were correlated with clinical and histopathological data, the nuclear IR for the Ki67 antigen (proliferation) of the neoplastic cells, and their IR against the p53 protein. Distinct CgA IR cells were found in 5 out of 47 (11%) tumours when studied by the conventional method, and in 9 out of 47 (19%) when examined by the TSA technique. Corresponding figures, if tumours with only questionable IR against CgA were also included, were 14 (30%) and 23 (50%), respectively. Out of the 9 cases with unequivocal CgA IR, only 3 displayed an IR to an additional hormone or growth factor; this hormone turned out to be somatostatin (only minimal foci). Insulin and glucagon cells also appeared exceptionally. The NE differentiation was found to be unrelated to proliferation, p53 protein expression, and to the survival of the patients. It occurred mainly (7 out of 9) in poorly differentiated adenocarcinomas. Thus, the plain NE immunoprofile of the CgA IR cells, together with the increased IR observed when the TSA technique was used, indicates that the NE cells in these adenocarcinomas are only poorly differentiated. When the CgA IR cells exceptionally become highly differentiated, they can express islet hormones. Using strict structural and IHC criteria, a NE differentiation occurs in less than 20 % of cases; its clinico-pathological significance seems to be non relevant.


Subject(s)
Carcinoma, Pancreatic Ductal/pathology , Neurosecretory Systems/pathology , Pancreatic Neoplasms/pathology , Aged , Aged, 80 and over , Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/metabolism , Cell Differentiation , Cell Proliferation , Chromogranin A , Chromogranins/metabolism , Female , Humans , Immunoenzyme Techniques , Ki-67 Antigen/metabolism , Male , Middle Aged , Neurosecretory Systems/metabolism , Pancreatic Neoplasms/metabolism , Prognosis , Tumor Suppressor Protein p53/metabolism
5.
Scand J Gastroenterol ; 39(10): 969-73, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15513336

ABSTRACT

BACKGROUND: Chromogranin A (CgA) has been shown to be a useful marker in the diagnosis of neuroendocrine (NE) tumours. The clinical significance of CgA has been studied mostly in patients with known NE tumours. The diagnosis was evaluated in 153 consecutive patients in whom CgA was measured in a given time interval. METHODS: CgA in serum was measured by radioimmunoassay. Immunohistochemistry with an antibody against CgA was performed in tumours from patients with adenocarcinoma and elevated CgA levels using a conventional method and the more sensitive tyramide signal amplification (TSA) technique. RESULTS: Elevated serum CgA levels were found in 44 patients; 19 had NE tumours and 6 had tumours classified as adenocarcinomas. With the TSA technique, a high proportion of CgA-positive cells were disclosed in five of the adenocarcinoma patients. Patients with atrophic gastritis (no. 2) and patients treated with inhibitors of gastric acid secretion (no. 6) also had elevated levels of CgA. A modest increase in CgA levels was observed in 2 patients with renal impairment, and in 9 patients without any obvious cause. CONCLUSION: The current study confirms that serum CgA is a sensitive marker for the detection of NE neoplasia. Elevated levels found in patients with adenocarcinoma may indicate NE differentiation in the tumour. CgA is a useful tool in the monitoring of enterochromaffin-like (ECL) hyperplasia secondary to treatment with acid secretion inhibitors or atrophic gastritis.


Subject(s)
Adenocarcinoma/diagnosis , Biomarkers, Tumor/blood , Chromogranins/blood , Gastrointestinal Neoplasms/diagnosis , Neuroendocrine Tumors/diagnosis , Adenocarcinoma/blood , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy, Needle , Child , Chromogranin A , Chromogranins/metabolism , Cohort Studies , Female , Gastrointestinal Neoplasms/blood , Humans , Immunohistochemistry , Male , Middle Aged , Neuroendocrine Tumors/blood , Probability , Prognosis , Radioimmunoassay , Sensitivity and Specificity , Severity of Illness Index , Statistics, Nonparametric
6.
Scand J Gastroenterol ; 39(7): 621-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15370681

ABSTRACT

BACKGROUND: Patients with chronic atrophic gastritis (CAG) and hypergastrinaemia are at risk of developing hyperplasia of the enterochromaffin-like (ECL) cells and ECL-cell-derived tumours. The effect of the somatostatin analogue octreotide on ECL cell carcinoids is examined. METHODS: Five patients with hypergastrinaemia and ECL cell carcinoids were enrolled in a 1-year study of octreotide LAR (long-acting release) 20 mg given at monthly intervals. Biopsies from tumours and from flat oxyntic mucosa were done at the start and 3, 6 and 12 months thereafter. Sections were stained with haematoxylin-erythrosin, immunostained with chromogranin A (CgA) and doublestained with CgA and Ki-67. Serum gastrin and CgA were measured. RESULTS: The number of visible tumours was reduced by more than 50 %. Sections from both tumours and flat mucosa showed a reduced number of CgA immunoreactive cells. Mean serum gastrin decreased from 421 to 186 pM (normal <40 pM); P > 0.05, and serum CgA from 73 to 25 ng/ml (normal < 30 ng/ml); P < 0.001. CONCLUSIONS: During treatment the patients were still markedly hypergastrinaemic, whereas the serum CgA showed normalization. A diminished tumour load and reduced ECL cell density were found, indicating an antiproliferative effect of octreotide directly on the ECL cells.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Carcinoid Tumor/drug therapy , Enterochromaffin-like Cells/drug effects , Octreotide/administration & dosage , Stomach Neoplasms/drug therapy , Aged , Carcinoid Tumor/pathology , Cell Proliferation/drug effects , Chromogranin A , Chromogranins/blood , Chromogranins/drug effects , Delayed-Action Preparations , Female , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Gastrins/blood , Gastrins/drug effects , Gastroscopy , Humans , Male , Middle Aged , Stomach Neoplasms/pathology , Time Factors
8.
Acta Physiol Scand ; 179(3): 251-62, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14616241

ABSTRACT

UNLABELLED: Previous reports indicate that H+/K+-adenosine triphosphatase (ATPase) might be expressed in the heart. AIMS: The objectives of the present study were to explore the presence of H+/K+-ATPase protein and gene expression in the rat heart and to investigate whether the enzyme could contribute to potassium transport across the sarcolemma. METHODS AND RESULTS: We performed reverse transcription-polymerase chain reaction (RT-PCR) on mRNA from myocardium and isolated cardiomyocytes using primers specific for the gastric H+/K+-ATPase alpha-subunit. The PCR products were sequenced and the predicted gastric H+/K+-ATPase sequence was verified. Western blots from myocardium detected a 34-kDa band and a 94-kDa band, indicating the beta-subunit and alpha-subunit of the gastric H+/K+-ATPase, respectively. Immunocytochemistry detected significant immunoreactivity of the beta-subunit in cardiomyocytes. H+/K+-ATPase-dependent potassium transport was assessed by 86Rb+-uptake in isolated cardiomyocytes. Both ouabain and the selective H+/K+-ATPase inhibitor Schering 28080 reduced 86Rb+-uptake at maximum specific inhibition, by 70 and 25%, respectively; the effects were additive. Competitive RT-PCR analysis indicated a significant upregulation of the myocardial H+/K+-ATPase in heart failure after myocardial infarction. CONCLUSION: The gastric isoform of H+/K+-ATPase is expressed in rat cardiac myocytes, both at transcript and protein levels. Functional studies indicate that the enzyme could contribute to potassium and pHi regulation in cardiomyocytes.


Subject(s)
Gene Expression Regulation/genetics , H(+)-K(+)-Exchanging ATPase/genetics , Heart/physiology , Adenosine Triphosphatases/antagonists & inhibitors , Animals , Biological Transport/genetics , Blotting, Western/methods , Enzyme Inhibitors/pharmacology , Female , Heart/drug effects , Imidazoles/pharmacology , Immunohistochemistry/methods , Myocardial Infarction/metabolism , Myocardium/metabolism , Ouabain/pharmacology , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction/methods , Rubidium Radioisotopes , Up-Regulation/genetics
9.
Dig Dis Sci ; 48(5): 906-10, 2003 May.
Article in English | MEDLINE | ID: mdl-12772787

ABSTRACT

Streptozotocin has been used to induce diabetes mellitus in experimental animals and has been thought to have a selective cytotoxic effect on the beta-cells in the islets of Langerhans. The aim of the present study was to determine whether streptozotocin has any cytotoxic effect on other neuroendocrine cells of the gastrointestinal tract. Eight female Sprague-Dawley rats received intraperitoneal injections of 100 mg/kg streptozotocin in citric acid buffer; the concentration of streptozotocin was adjusted to 25 mg/ml buffer. Seven rats, serving as controls, received an equivalent volume of the vehicle. The rats were killed after three days and the fundus, antrum, small intestine and pancreas were examined for neuroendocrine cells. Our study confirms that streptozotocin is cytotoxic towards beta-cells. In addition, it is cytotoxic towards neuroendocrine cells of the oxyntic mucosa of the stomach. This finding may have clinical significance and suggests that streptozotocin may be used in the treatment of gastric neuroendocrine tumors as well as insulinomas.


Subject(s)
Neurosecretory Systems/cytology , Neurosecretory Systems/drug effects , Pancreas/drug effects , Pancreas/pathology , Streptozocin/toxicity , Animals , Biopsy, Needle , Digestive System/cytology , Digestive System/drug effects , Digestive System/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Gastric Mucosa/drug effects , Gastric Mucosa/pathology , Immunohistochemistry , Injections, Intraperitoneal , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Islets of Langerhans/drug effects , Islets of Langerhans/pathology , Pancreas/cytology , Probability , Rats , Rats, Sprague-Dawley , Reference Values , Risk Assessment , Streptozocin/pharmacology
10.
APMIS ; 110(9): 658-64, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12529020

ABSTRACT

The aim of the study was to determine if, by means of tyramide signal amplification (TSA), the presence of chromogranin A (CgA)-positive tumour cells could be demonstrated in breast cancer cases found to be negative by conventional immunohistochemical staining. Sections from 44 cases of breast cancer (28 infiltrating ductal carcinomas, 2 lobular carcinomas, 4 ductal carcinomas in situ (DCIS), 7 lobular carcinomas in situ (LCIS), and 3 mucinous carcinomas) were stained for CgA by conventional immunohistochemical methods and by immunohistochemistry with TSA. The sections were also histologically graded and their oestrogen receptor (ER), progesterone receptor (PgR) and HER-2 oncogene status was recorded. Five of the tumours showed CgA-positive staining with the polyclonal antibody 430 with conventional methods. Thirty cases showed CgA-immunoreactive tumour cells after immunohistochemical staining with the polyclonal antibody 430 with TSA. However, eight of these also showed faint staining with the negative control antibody X0936 with TSA. One case showed immunopositivity for CgA using a monoclonal antibody without tyramide amplification and only a further two cases were positive when TSA was applied. The presence of CgA appears to be associated with a lower histological grade and may be more often found in oestrogen receptor-positive tumours.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/metabolism , Carcinoma, Neuroendocrine/metabolism , Chromogranins/analysis , Immunohistochemistry/methods , Adenocarcinoma, Mucinous/metabolism , Antibodies , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Intraductal, Noninfiltrating/metabolism , Carcinoma, Lobular/metabolism , Carcinoma, Neuroendocrine/pathology , Cell Differentiation , Chromogranin A , Female , Humans , Sensitivity and Specificity , Tyramine
11.
Scand J Gastroenterol ; 36(11): 1128-33, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11686210

ABSTRACT

BACKGROUND: The interrelationship between histamine and gastrin in the physiological regulation of gastric acid secretion is still a matter of dispute. CCK-2 receptors are located on enterochromaffin-like (ECL) cells in corpus mucosa and gastrin stimulates acid production by releasing histamine from the ECL cells, which in turn stimulates the parietal cells. Whether parietal cells also possess gastrin receptors of physiological significance is unclear. The aim of the present study was to localize the CCK-2 receptor cellularly and concomitantly demonstrate a gastrin receptor response (histamine release). METHODS: Fluorescein labelled cholecystokinin-8 (Fluo-CCK-8) was added to the arterial infusion to totally isolated, vascularly perfused rat stomachs to a final concentration of 130 pmol L(-1) for 1 min, either alone or along with 520 nmol(-1) CCK-8 after 10-min pre-perfusion with CCK-8. Immediately after the Fluo-CCK-8 had reached the oxyntic mucosa, biopsies were taken and the binding sites were localized by double immunohistochemistry combined with the tyramide signal amplification (TSA) technique. Venous histamine was measured before and during stimulation. RESULTS: Fluo-CCK-8 (130 pM) evoked histamine release, and binding sites were found in the basal part of corpus mucosa, co-localized with histidine decarbocylase (HDC) immunoreactive ECL cells. No binding of Fluo-CCK was found in the mid-glandular region of corpus, dominated by parietal cells. Binding of Fluo-CCK-8 was abolished by concomitant perfusion with excess CCK-8. CONCLUSION: Fluo-CCK-8 given to isolated rat stomachs in a physiological concentration binds to CCK-2 receptors on ECL cells and causes histamine release, whereas no binding of Fluo-CCK-8 to parietal cells was found.


Subject(s)
Enterochromaffin-like Cells/chemistry , Parietal Cells, Gastric/chemistry , Receptors, Cholecystokinin/analysis , Animals , Binding Sites , Histamine Release/physiology , Immunohistochemistry , In Vitro Techniques , Male , Rats , Rats, Wistar , Sincalide/administration & dosage
13.
J Bone Miner Res ; 16(8): 1426-33, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11499865

ABSTRACT

The adipose hormone leptin and its receptor are important for regulation of food intake and energy metabolism. Leptin also is involved in the growth of different tissues. In this study, we show the expression of leptin in primary cultures of normal human osteoblasts (hOBs) as evidenced by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunocytochemistry. Release of leptin into the medium also was found. Leptin was not detected in commercially available hOBs (NHOst) or in three different human monoclonal osteosarcoma cell lines. Leptin expression was observed in OBs in the mineralization and/or the osteocyte transition period but not during the matrix maturation period. Furthermore, hOBs and osteosarcoma cell lines expressed the long signal-transducing form of the leptin receptor (OB-Rb) as shown by RT-PCR. We observed no significant changes in leptin or OB-Rb genes in hOBs after incubation with recombinant leptin, indicating no autoregulation of the leptin expression. Incubation of both hOBs entering the mineralization phase and osteosarcoma cell lines with recombinant leptin markedly increased the number of mineralized nodules as shown by alizarin S staining. These findings indicate that leptin may be of importance for osteoblastic cell growth and bone mineralization.


Subject(s)
Calcification, Physiologic/physiology , Leptin/metabolism , Osteoblasts/physiology , Receptors, Cell Surface , 3T3 Cells , Animals , Calcification, Physiologic/drug effects , Carrier Proteins/genetics , Cells, Cultured , Femur/cytology , Gene Expression , Humans , Ilium/cytology , Leptin/genetics , Leptin/pharmacology , Leptin/physiology , Mice , Osteoblasts/cytology , Osteoblasts/metabolism , Receptors, Leptin , Recombinant Proteins/pharmacology , Tumor Cells, Cultured
14.
Appl Immunohistochem Mol Morphol ; 9(1): 9-13, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11277422

ABSTRACT

With regard to the cellular origin of bronchial squamous-cell carcinomas, there are some clinicopathologic and experimental data indicating a link between neuroendocrine (NE) bronchial tumors and the traditionally non-NE squamous-cell carcinomas. Against this background, 29 consecutively resected bronchial squamous-cell carcinomas were examined immunohistochemically (IHC) by means of the specific NE cell marker chromogranin A (CgA), using not only conventional IHC methods, but also the technique with increased sensitivity, offered by the tyramide signal amplification (TSA) procedure. Whereas none of the 29 tumors displayed CgA immunoreactive (IR) cells using the conventional IHC procedure, 10 were found to display a fine granular CgA IR in the neoplastic parenchymal cells using the TSA technique. This incidence is higher than previously reported. However, the CgA IR cells never formed any majority cell population of the neoplastic parenchyma; when present, most of them occurred as micronodules or larger confluent areas in the peripheral most undifferentiated parts of the carcinomatous sheets. Single CgA IR cells were detected only rarely in the spinocellular or keratinized areas. It can be speculated that the observations conform with the recently proposed hypothesis that there is a reservoir of NE progenitor cells in the bronchial mucosa capable of proliferation.


Subject(s)
Bronchial Neoplasms/metabolism , Bronchial Neoplasms/pathology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Biomarkers, Tumor/metabolism , Biotin/analogs & derivatives , Carcinoma, Small Cell/metabolism , Carcinoma, Small Cell/pathology , Cell Differentiation , Chromogranin A , Chromogranins/metabolism , Humans , Immunohistochemistry/methods , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Neurosecretory Systems/metabolism , Tyramine/analogs & derivatives
16.
Histochem J ; 32(9): 551-6, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11127976

ABSTRACT

Neuroendocrine cells are often disclosed in human gastric adenocarcinomas and may be recognised by their immunoreactivity towards chromogranin A. However, in dedifferentiated neuroendocrine tumour cells, the chromogranin A content may be reduced making it difficult to detect with conventional immunohistochemical methods. We therefore used a sensitive signal amplification technique in order to evaluate chromogranin A immunoreactivity and thus neuroendocrine differentiation in 40 gastric adenocarcinomas. Neuroendocrine cells were visualised by means of a monoclonal chromogranin A antibody and the avidin-biotin peroxidase complex technique, without and with addition of tyramide signal amplification. Double immunohistochemistry towards chromogranin A and Ki-67 were used to disclose proliferation in the neoplastic cells. A marked increase in the number of carcinomas containing chromogranin A-immunoreactive neoplastic cells was noted when applying the tyramide signal amplification technique. In addition, the number of immunoreactive cells within each tumour increased, and in some cases almost all the neoplastic cells became immunoreactive. Chromogranin A-immunoreactive tumour cells showing signs of proliferation were found in the majority of these carcinomas. In conclusion, we have disclosed widespread immunoreactivity towards chromogranin A in a proportion of gastric adenocarcinomas when enhancing the signal with tyramide signal amplification. Neuroendocrine differentiation is thus a common finding in gastric carcinomas when using sensitive methods.


Subject(s)
Adenocarcinoma/chemistry , Biomarkers, Tumor/analysis , Chromogranins/analysis , Stomach Neoplasms/chemistry , Adenocarcinoma/pathology , Chromogranin A , Humans , Immunoenzyme Techniques , Ki-67 Antigen/analysis , Sensitivity and Specificity , Stomach Neoplasms/pathology
17.
Br J Haematol ; 109(4): 815-22, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10929035

ABSTRACT

Binding of urokinase (uPA) to its receptor (uPAR; CD87) focuses proteolytic activity on the cell surface and this system is of importance in malignant matrix degradation and tumour invasion. By immunocytochemistry and flow cytometry, we found that primary myeloma cells and myeloma cell lines expressed uPA and uPAR. Soluble uPA was present in cell line supernatants and lysates in low concentrations. In cell lines, uPA and uPAR were located both on the cell surface and intracellularly, but the expression of both proteins was low. Higher levels of uPAR was detected on the cell surface of primary myeloma cells. When primary myeloma cells were gated by CD45 expression, stronger expression was found on immature CD45+ cells than on mature CD45-/dim cells. Finally, both myeloma cell lines and primary cells were able to cleave a uPA-specific substrate showing that the uPA system is functionally active. We conclude that myeloma cells are able to produce uPA and uPAR. This opens up a possible role of the uPA system in myeloma cell invasion and in the proteolytic digestion of bone matrix.


Subject(s)
Multiple Myeloma/metabolism , Plasminogen Activators/analysis , Receptors, Cell Surface/analysis , Urokinase-Type Plasminogen Activator/analysis , Flow Cytometry , Humans , Immunohistochemistry , Receptors, Urokinase Plasminogen Activator , Tumor Cells, Cultured
18.
Tidsskr Nor Laegeforen ; 120(2): 236-8, 2000 Jan 20.
Article in Norwegian | MEDLINE | ID: mdl-10851922

ABSTRACT

Immunohistochemistry is used for in situ detection of proteins in histological slides and is now an important diagnostic tool. Due to several methodological and biological factors, conventional immunohistochemical procedures may sometimes have too low sensitivity, especially for tracing the histogenesis of malignant tumours. A few years ago, an amplification technique was introduced which greatly increased the sensitivity of some of the commonly used immunohistochemical methods. This technique permits the use of primary antibodies in significantly lower concentrations compared with the conventional methods. Alternatively, one can keep the antibody concentration unchanged and use the enhanced sensitivity to detect scarce proteins, which are not visualised by traditional immunohistochemical procedures. We present a brief description of the technique and show some examples of its use in the diagnosis of neuroendocrine carcinomas. Tyramide signal amplification might become an important supplement for the diagnosis and classification of malignant tumours.


Subject(s)
Endocrine Gland Neoplasms/diagnosis , Tyramine/metabolism , Avidin/metabolism , Biotin/metabolism , Bronchi/metabolism , Bronchi/pathology , Carcinoma, Small Cell/diagnosis , Endocrine Gland Neoplasms/metabolism , Endocrine Gland Neoplasms/pathology , Female , Humans , Immunohistochemistry/methods , Lung Neoplasms/diagnosis , Ovarian Neoplasms/diagnosis , Peroxidase/metabolism , Sympathomimetics/metabolism
19.
Acta Physiol Scand ; 169(1): 29-37, 2000 May.
Article in English | MEDLINE | ID: mdl-10759608

ABSTRACT

Gastrin has a general growth-promoting effect on gastric oxyntic mucosa, and a more pronounced one on the enterochromaffin-like (ECL) cell. Whether gastrin has a proliferative effect on the parietal cell lineage beyond the general effect is uncertain. Hypergastrinaemia was evoked in rats using pantoprazole (group II: 100 micromol kg-1, group III: 400 micromol kg-1) for 45 days. Plasma gastrin was 43 +/- 8 pmol L-1 (control), 283 +/- 54 pmol L-1 (group II) and 577 +/- 63 pmol L-1 (group III). Gastric mucosal cells were isolated and fractionated by elutriation centrifugation. Total cell number, percentage and number of ECL and parietal cells, and histamine were determined in each fraction. The number of mucosal cells increased 1.5-fold in both hypergastrinaemic groups. Enterochromaffin-like cell content was 2.6 +/- 0.5% (control), 6.0 +/- 0.6% (group II) and 9.0 +/- 0.8% (group III). Histamine concentration in oxyntic mucosal cells rose similarly. The size of the ECL cells was 8.5 +/- 0.1 microm (control), 10.8 +/- 0.2 microm (group II) and 12.1 +/- 0.2 microm (group III), and the increased size was confirmed by shifted distribution in elutriation fractions. Histamine per ECL cell increased with cell size. The number of parietal cells increased parallel to the total number of mucosal cells (1.5-fold). Parietal cell size and percentage, assessed by image analysis and distribution in elutriation fractions, were unchanged after pantoprazole dosing. Gastrin has a pronounced, concentration-dependent specific trophic effect on ECL cells and a general proliferative effect on gastric mucosa, including parietal cells.


Subject(s)
Enterochromaffin Cells/drug effects , Enterochromaffin Cells/ultrastructure , Gastric Mucosa/pathology , Parietal Cells, Gastric/drug effects , Parietal Cells, Gastric/ultrastructure , 2-Pyridinylmethylsulfinylbenzimidazoles , Animals , Benzimidazoles/pharmacology , Cell Division/drug effects , Cell Fractionation/methods , Centrifugation/methods , Cytoplasmic Granules/ultrastructure , Enzyme Inhibitors/pharmacology , Female , Gastrins/blood , Histamine/blood , Hyperplasia , Microscopy, Electron , Omeprazole/analogs & derivatives , Pantoprazole , Rats , Rats, Sprague-Dawley , Sulfoxides/pharmacology
20.
Carcinogenesis ; 21(1): 23-7, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10607729

ABSTRACT

We have identified cotton rats with a high female-predominant occurrence of spontaneous gastric carcinomas localized to the oxyntic mucosa, classified as malignant enterochromaffin-like (ECL) omas. The present study was made to further characterize these ECLomas and surrounding oxyntic mucosa, both morphologically using histochemical and immunohistochemical methods, and for gene expression by northern blot analysis. Among eight female cotton rats, three had an irregularly thickened oxyntic mucosa, increased stomach weight and a high serum gastrin level. Histopathological examination showed adenomatous hyperplasia of the thickened oxyntic mucosa with areas of an invasive neoplastic tumour. Immunohistochemistry, using the general neuroendocrine cell marker chromogranin A (CgA) and the specific ECL cell marker histidine decarboxylase (HDC), showed a considerably increased ECL cell density. These ECL cells displayed active proliferation, with hyperplasia, dysplasia and neoplasia. Parietal cells were not found in the tumour tissue. Parietal cell density was only slightly reduced in the surrounding oxyntic mucosa. The antral mucosa was histopathologically normal with a normal number of gastrin-immunoreactive cells. Likewise, somatostatin-immunoreactive cells did not show any differences in the antral and oxyntic mucosa between rats with pathological and normal oxyntic mucosa. Northern blot analysis revealed increased expression of CgA and HDC mRNA in the thickened oxyntic mucosa, whereas H(+)/K(+) ATPase mRNA was similar in the oxyntic mucosa of those with thickened and normal oxyntic mucosa. Gastrin mRNA in the antral mucosa was high in animals with thickened oxyntic mucosa. Somatostatin mRNA expression was similar in the antral mucosa of control animals and animals with a thickened oxyntic mucosa. We conclude that the spontaneous gastric carcinoma occurring in female cotton rats is an ECLoma developing secondary to hypergastrinaemia due to reduced intragastric pH. The mechanism for reduced acidity is not known, but is not gastric atrophy.


Subject(s)
Enterochromaffin Cells/pathology , Gastrins/blood , Parietal Cells, Gastric/pathology , Rodent Diseases/etiology , Sigmodontinae , Stomach Neoplasms/veterinary , Animals , Blotting, Northern , Chromogranin A , Chromogranins/analysis , Chromogranins/genetics , Female , Gastric Acidity Determination , H(+)-K(+)-Exchanging ATPase/metabolism , Histidine Decarboxylase/genetics , Immunohistochemistry , RNA, Messenger/analysis , Rodent Diseases/pathology , Somatostatin/genetics , Stomach Neoplasms/etiology , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...